317358-03-5

Upstream product

• 1159114-52-9 tert-butyl (2S,4R)-4-azido-2-(((tert-butyldiphenylsilyl)oxy)methyl)pyrrolidine-1-carboxylate 
• 1159114-51-8 tert-butyl (2S,4S)-2-(((tert-butyldiphenylsilyl)oxy)methyl)-4-((methylsulfonyl)oxy)-pyrrolidine-1-carboxylate 
• 74844-91-0 (2S,4S)-N-tert-butoxycarbonyl-4-hydroxyproline methyl ester 
• 148017-38-3 tert-butyl (2S,4S)-2-(hydroxymethyl)-4-((methylsulfonyl)oxy)pyrrolidine-1-carboxylate 
• 121147-93-1 (2S,4S)-2-methyl N-Boc-4-((methylsulfonyl)oxy)pyrrolidine-2-carboxylate 

Downstream Products

• 1159114-55-2 C₂₇H₃₇F₃N₂O₅SSi 
• 1159114-57-4 C₂₇H₄₀N₂O₅SSi 
• 1159114-56-3 C₃₃H₄₄N₂O₅SSi 
• 1167989-60-7 C₂₇H₃₆N₂O₃SSi 
• 1159114-40-5 1-(3,5-bis(trifluoromethyl)phenyl)-3-((3R,5S)-5-((tert-butyldiphenylsilyloxy)methyl)pyrrolidin-3-yl)thiourea 
• 1159114-41-6 C₂₈H₃₅N₃OSSi 
• 1159114-42-7 C₂₉H₃₇N₃O₂SSi 
• 1159114-43-8 4-trifluoromethanesulfonamidyl prolinol tert-butyldiphenylsilyl ether 
• 1159114-44-9 C₂₈H₃₆N₂O₃SSi 
• 1283136-21-9 N-((3R,5S)-5-((tert-butyldiphenylsilyloxy)methyl)pyrrolidin-3-yl)-3,5-bis(trifluoromethyl)benzenesulfonamide 
• 1372972-14-9 C₃₅H₄₁F₆N₃O₄Si 
• 1372971-95-3 1-(3,5-bis(trifluoromethyl)phenyl)-3-((3R,5S)-5-((tert-butyldiphenylsilyloxy)methyl)pyrrolidin-3-yl)urea 
• 1372972-17-2 C₃₄H₄₁F₆N₃O₅SSi 
• 1372971-97-5 N-(3,5-bis(trifluoromethyl)phenyl)-N'-((3R,5S)-5-((tert-butyldiphenylsilyloxy)methyl)pyrrolidin-3-yl)sulfamide 

Relevant academic research and scientific papers

Highly efficient asymmetric anti-Mannich reactions of carbonyl compounds with N-carbamoyl imines catalyzed by amino-thiourea organocatalysts

A series of pyrrolidine-based organocatalysts which bear three synergistic features, i.e. secondary amino group, various H-bond donor groups at the 4-position and a stereocontrol silyl ether group at the α-position of the pyrrolidine nitrogen atom, were d

A facile direct anti-selective catalytic asymmetric Mannich reaction of aldehydes with preformed N-Boc and N-Cbz imines

Anti-selective Mannich reactions of N-Boc and N-Cbz protected imines with unmodified aldehydes proceeded smoothly under the catalysis of a secondary amine-thiourea catalyst, which led to high yields (70%-95%) and excellent enantioselectivity (up to 964 dr

Highly enantioselective Michael addition reactions in water catalyzed by an insoluble MPS-supported 4-sulfonamidyl prolinol tert-butyldiphenylsilyl ether

The development of a highly efficient, insoluble, and non-swelling MPS-supported organocatalyst for the direct asymmetric Michael reaction of ketones and aldehydes to nitrostyrenes at room temperature in water is described. Excellent yields (up to 100%) a

4-Trifluoromethanesulfonamidyl prolinol tert-butyldiphenylsilyl ether as a highly efficient bifunctional organocatalyst for Michael addition of ketones and aldehydes to nitroolefins

4-Trifluoromethanesulfonamidyl prolinol tert-butyldiphenylsilyl ether bifunctional organocatalyst 3a is a highly efficient catalyst for the asymmetric Michael addition reactions of ketones and aldehydes to nitrostyrenes, leading to syn-selective adducts with excellent yields (>99%), high diastereoselectivities (up to 99:1 dr) and excellent enantioselectivities (up to 99% ee). Control experiments suggested that the trans-configuration relationship between the bulky group (-CH2OTBDPS) and the sulfonamido group at the 4-position of the pyrrolidine ring was important to achieve high yield and stereoselectivity.

VLA-4 inhibitor compounds

Compounds that selectively inhibit the binding of ligands to alpha4beta1 integrin (VLA-4) and methods for their preparation are disclosed. In one embodiment, compounds of the invention are represented by Formula I: As selective inhibitors of VLA-4 mediated cell adhesion, compounds of the present invention are useful in the treatment of conditions associated with such adhesion, including, but not limited to, such conditions as inflammatory and autoimmune responses, diabetes, asthma, psoriasis, inflammatory bowel disease, transplantation rejection, and tumor metastasis. Also disclosed are pharmaceutical compositions, methods of inhibiting VLA-4 mediated cell adhesion and methods of treating conditions associated with LA-4 mediated cell adhesion, which involve compounds of Formula I.